N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 / Phase 2 ClinicalTrials.gov

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Sponsor: Regeneron Pharmaceuticals • ClinicalTrials.gov ID: NCT07455851

Registry updated: 2026-09-11
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This study is researching a drug called REGN17372 used with another drug called linvoseltamab (each individually called "study drug" or "study drugs" when combined) in participants with relapsed (when a tumor comes back) or refractory (when a tumor does not respond to treatment) multiple myeloma. This study is the first time REGN17372 will be given to humans. The aim of the study is to understand if REGN17372 can be given safely with linvoseltamab, and if so, what dosing regimen should be used for this treatment combination, in comparison with linvoseltamab alone. The study is looking at: * What side effects may happen from taking REGN17372 with linvoseltamab * How well REGN17372 and linvoseltamab, or linvoseltamab alone, work in treating multiple myeloma * What is the best dose of REGN17372 when given with linvoseltamab * How much study drug(s) are in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the study drugs less effective or could lead to side effects) * If and how REGN17372 and linvoseltamab affect the overall quality of life, daily activities, symptoms and treatment side effects based on participant own feedback (Phase 2)

Interventions

  • Linvoseltamab (Drug)
    Administered per protocol
  • REGN17372+Linvoseltamab (Drug)
    Administered per the protocol

Eligibility criteria

Key Inclusion Criteria: 1. Participants with RRMM who have exhausted (or are not a candidate for) all therapeutic options that are expected to provide meaningful clinical benefit and have received at least 3 lines of therapy as defined in the protocol 2. ECOG performance status score ≤1 3. Participants must have measurable disease for response assessment as described in the protocol 4. Adequate hematologic, cardiac, hepatic, and renal function, as described in the protocol Key Exclusion Criteria: 1. Participants with non-secretory MM, active plasma cell leukemia, known amyloidosis, Waldenström macroglobulinemia, or known POEMS syndrome as defined in the protocol 2. Participants who have known MM brain lesions or CNS involvement 3. Participants with a history of PML, a neurocognitive condition or CNS movement disorder, or a history of seizure within 12 months prior to entering screening 4. Prior treatment with GPRC5D-directed immunotherapies (phase 1 and phase 2) and/or prior treatment with a BCMAxCD3 bispecific antibody (phase 2) Note: Other protocol defined inclusion/exclusion criteria apply

Conditions

Relapsed Refractory Multiple Myeloma (RRMM)

Locations

  • Prince of Wales Hospital — Randwick, New South Wales, Australia
  • Illawarra Cancer care centre, Wollongong Hospital — Wollongong, New South Wales, Australia
  • Royal Adelaide Hospital — Adelaide, South Australia, Australia
  • St Vincents Hospital Melbourne — Fitzroy, Victoria, Australia
  • Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia
  • Alfred Hospital — Melbourne, Victoria, Australia
  • Evangelismos General Hospital — Athens, Attica, Greece
  • Alexandra Hospital — Athens, Attica, Greece
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record